We look back to the 1990s, and to our ‘first-in-man’ trial of prostate cancer drug abiraterone – a vital step in the drug’s development
We spoke to two of our own experts about how they’re targeting fundamental repair processes in our cells to tip cancer cells over the edge.
We take a look at what a new class of drugs called PARP inhibitors are doing to fight womb cancer.
In light of a preliminary ‘no’ from NICE over olaparib for ovarian cancer, we hear from one of our experts whose work led to the drug’s development
New immunotherapy results from a big US conference, another first step towards ‘personalised cancer vaccines’, plus what’s an ‘injectable lab’?
Our researchers are investigating the genetic ‘patchwork’ underlying ovarian tumours, which will lead to more effective treatments in the future.
We look at fascinating new research from our scientists showing that pancreatic cancer can be split into four different types.
A Lethal Weapon against cancer? Researchers are using ‘synthetic lethality’ to develop new treatments based on targeting DNA repair processes.
Government science funding announcement, exercise and prostate cancer, plus a handful of stories about drug approval – here’s the week’s cancer news.